Sepsis is a kind of disease in which the body’s reaction to an infection is so strong that it damages its organs and tissues. Sepsis, severe sepsis, and septic shock are the three different conditions depending on the severity of the infection.
The market for sepsis diagnostics in 2021 was USD 712.74 million, and by 2030, it will be worth USD 1509.85 million, growing at a 8.7% CAGR during the forecast period.
Factors stimulating the market’s growth are the increased rates of sepsis, the availability of technologically sophisticated diagnostic tools, and rising public knowledge. Sepsis is one of the life-threatening diseases, according to the WHO, and it impacts about 30 million people worldwide and results in about 6 million fatalities annually. Around the world, sepsis affects 3 million newborns and 1.2 million children annually.
The demand for sepsis diagnostics is driven by the rising prevalence of hospital-acquired infections that result in sepsis, especially in the geriatric population, infants, and patients with chronic illnesses. The increasing prevalence of numerous infectious illnesses caused by gram-positive and gram-negative bacilli that are resistant to antibiotics is another factor driving the demand for sepsis diagnostics. Additionally, the sepsis diagnosis market is growing due to the expanding healthcare industry and the rising use of sophisticated data analytics tools. The integration of numerous test results from various platforms made possible by these data analytics tools has allowed for real-time data access and precise disease diagnosis. Additionally, several technological developments have produced new immunological and molecular biomarkers that allow for the early recognition of sepsis.
One of the main issues in sepsis management is the lack of education about sepsis. Outside of intensive care medicine, most clinical practitioners and emergency physicians are unaware of sepsis.
- Sepsis is more common in the elderly and neonatal populace due to their weak immune system. The growing geriatric population will provide numerous growth opportunities in the future.
- Presently, novel biomarkers for the detection of sepsis are currently developing. The increasing prevalence of sepsis and infectious diseases will drive the demand for novel diagnostic approaches.
In the year 2022, the microbiology segment ruled the entire market with a revenue share of nearly 50%. Microbiology enables the quantitative detection of microorganisms causing sepsis with the help of culture media testing like bacteriology and serology tests. Primary factors influencing the growth of this segment are:
- The growing investments in clinical labs.
- Rising awareness among researchers and scientists about microbiological testing.
- Rising incidences of infectious disease.
The blood culture segment was the largest market in 2022, with a revenue share of nearly 40%. It is due to the widespread use of the blood culture method in sepsis analysis due to its cost-efficiency and usage suitability.
By Diagnostic Methods
The automated diagnostics segment was the largest market contributor in 2022. It is mainly due to its high efficacy, enhanced traceability, and elimination of repeated diagnostic techniques. Additionally, the main players’ implementation of numerous business development plans and the surge in demand for the prompt treatment of illnesses are making it simple to obtain automated sepsis diagnosis equipment and consumables.
In 2022, the bacterial sepsis segment ruled the entire market with 80% of the revenue share. The largest share of this segment is due to the rising rate of bacterial sepsis, increasing incidence of HAIs, and rising frequency of surgical procedures.
By Testing Type
The laboratory segment held a maximum position in the market, with a revenue share of nearly 85% in 2021. This is primarily because lab testing is more accurate than POC testing for diagnosing sepsis. An extensive study of the pathogen and its drug resistance profile is provided by clinical laboratory testing.
North America held the largest position in the regional market, with a revenue share of nearly 40% in 2022. It is mainly due to the high sepsis mortality rate in this region. This development is due to the region’s increased use of sophisticated diagnostic tools due to strong healthcare infrastructure. Additionally, the market development in this area is driven by the substantial presence of key players and a favorable reimbursement framework.
Furthermore, Asia Pacific will expand rapidly with a 10% CAGR during the forecast period. This is due to the increase in product clearances and the surge in spending on research and development for improved diagnostic tools. Japan and China together owned an approximately 50% revenue share in the region in 2022, driven by their rapid economic growth.
- Hoffmann-La Roche AG
- Danaher Corporation (Beckman Coulter, Inc.)
- Becton, Dickinson, and Company
- BioMérieux SA
- Thermo Fisher Scientific, Inc.
- Bruker Corporation
- Amara Health Analytics
- GE Healthcare
- Luminex Corporation
- Wolters Kluwer NV.
- Epic Systems Corporation
- Cerner Corporation
- Mckesson Corporation
- Koninklijke Philips N.V.
The market for sepsis diagnostics in 2021 was USD 712.74 million, and by 2030 it will be worth USD 1509.85 million, growing at a 8.7% CAGR during the forecast period. The market growth is driven by the increasing rate of hospital-acquired infections and sepsis cases and the numerous actions made by the government and healthcare organizations to support research into the detection and effective treatment of these conditions.
As per the information distributed by the WHO in April 2018, worldwide, this condition influences in excess of 30 million individuals and prompts around 6 million passings consistently. A similar source expresses that universally, around 3 million babies and 1.2 million kids experience the ill effects of this condition consistently. Such a high commonness is expected to increment interest for its demonstrative arrangements, subsequently powering the market development over the estimate period. The episode of novel Covid (Coronavirus) and an ensuing expansion in the gamble of creating. Sepsis are a portion of the key donors driving the interest for diagnostics arrangements.
As per the Worldwide Sepsises Partnership in April 2020, around 30% of Coronavirus patients had proof of liver injury. And around 75% detailed a discouraged resistant reaction in Seattle, U.S. Accord. According to the Worldwide Sepsis Collusion, infections liable for Coronavirus, flu, pneumonia, meningitis, and others are basically answerable for causing sepsis. In light of a review study, hospitalized Coronavirus patients represent a higher gamble of creating coinfections.
Compression Therapy Market Report – The global compression therapy market will witness a robust CAGR of 5.2%. Valued at $2.98 billion in 2021, expected to appreciate and reach $4.71 billion by 2030, confirms Strategic Market Research.